Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 10x Genomics, Inc.TXG · Entity 2172 | Director · Chief Executive Officer | September 22, 2026 | September 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
10x Genomics, Inc.
Report date September 22, 2026 · Filed September 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 1,050,249 |
Ending reported balance
After 2026-09-22 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-09-22 · Sale · Disposed 1,000 · Balance 1,074,249 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F2: This transaction was executed in multiple trades at prices ranging from $77.75 to $78.73, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 2 · 2026-09-22 · Sale · Disposed 2,000 · Balance 1,072,249 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F3: This transaction was executed in multiple trades at prices ranging from $79.11 to $80.07, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 3 · 2026-09-22 · Sale · Disposed 9,300 · Balance 1,062,949 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F4: This transaction was executed in multiple trades at prices ranging from $80.28 to $81.27, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 4 · 2026-09-22 · Sale · Disposed 9,900 · Balance 1,053,049 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F5: This transaction was executed in multiple trades at prices ranging from $81.28 to $82.25 inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 5 · 2026-09-22 · Sale · Disposed 2,800 · Balance 1,050,249 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F6: This transaction was executed in multiple trades at prices ranging from $82.28 to $82.53, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 27 |
Reported balance
Holding disclosure · report date 2026-09-22 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 27 F7: The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 213,250 |
Reported balance
Holding disclosure · report date 2026-09-22 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 213,250 F8: The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 71,644 |
Reported balance
Holding disclosure · report date 2026-09-22 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 71,644 F9: The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025.
F2: This transaction was executed in multiple trades at prices ranging from $77.75 to $78.73, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3: This transaction was executed in multiple trades at prices ranging from $79.11 to $80.07, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4: This transaction was executed in multiple trades at prices ranging from $80.28 to $81.27, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5: This transaction was executed in multiple trades at prices ranging from $81.28 to $82.25 inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F6: This transaction was executed in multiple trades at prices ranging from $82.28 to $82.53, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F7: The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.
F8: The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.
F9: The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 08, 2021 Filed Jun 10, 2021 20:25 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 5,209 | $5.04 | $26,253.36 |
DisclosureSEC source: 0001209191-21-039445 · doc4.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 909,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| June 04, 2021 Filed Jun 10, 2021 20:25 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GiftClass A Common Stock | 200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-039445 · doc4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 904,068 Read SEC document |
| May 24, 2021 Filed May 27, 2021 00:27 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 771 | $162.66 | $125,410.55 |
DisclosureSEC source: 0001209191-21-036104 · doc4.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 904,268 F3 · shares: These shares were sold to cover tax withholding obligations in connection with the vesting of RSUs. F4 · balance_after: The number of shares beneficially owned following the reported transaction is as of May 24, 2021. Read SEC document |
| May 04, 2021 Filed May 5, 2021 21:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 9,792 | $0.00 Strike: $11.48 | $0.00 |
DisclosureSEC source: 0001209191-21-030400 · doc4.xml · derivative · entry 13 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,296 Underlying: Class A Common Stock · 9,792 shares Expires 2029-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F11 · derivative.exercise_date: This option, originally for 145,786 shares, of which 48,490 have been exercised, vested as to one forty-eighth of the shares on May 1, 2019, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| May 04, 2021 Filed May 5, 2021 21:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 5,208 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-21-030400 · doc4.xml · derivative · entry 12 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,782 Underlying: Class A Common Stock · 5,208 shares Expires 2028-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F10 · derivative.exercise_date: This option, originally for 250,000 shares, of which 160,218 have been exercised, vested as to one forty-eighth of the shares on October 1, 2018, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| May 04, 2021 Filed May 5, 2021 21:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 200 | $188.75 | $37,749.00 |
DisclosureSEC source: 0001209191-21-030400 · doc4.xml · nonDerivative · entry 11 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 880,468 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F9 · price: This transaction was executed in multiple trades at prices ranging from $188.61 to $188.88. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 04, 2021 Filed May 5, 2021 21:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 100 | $186.75 | $18,675.00 |
DisclosureSEC source: 0001209191-21-030400 · doc4.xml · nonDerivative · entry 10 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 880,668 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| May 04, 2021 Filed May 5, 2021 21:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,100 | $185.91 | $204,504.52 |
DisclosureSEC source: 0001209191-21-030400 · doc4.xml · nonDerivative · entry 9 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 880,768 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · price: This transaction was executed in multiple trades at prices ranging from $185.61 to $186.37. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 04, 2021 Filed May 5, 2021 21:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,951 | $185.04 | $546,042.12 |
DisclosureSEC source: 0001209191-21-030400 · doc4.xml · nonDerivative · entry 8 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 881,868 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $184.61 to $185.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 04, 2021 Filed May 5, 2021 21:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 6,644 | $184.20 | $1,223,854.70 |
DisclosureSEC source: 0001209191-21-030400 · doc4.xml · nonDerivative · entry 7 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 884,819 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $183.61 to $184.60. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 04, 2021 Filed May 5, 2021 21:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,100 | $183.06 | $384,417.81 |
DisclosureSEC source: 0001209191-21-030400 · doc4.xml · nonDerivative · entry 6 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 891,463 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $182.56 to $183.55. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 04, 2021 Filed May 5, 2021 21:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,200 | $182.14 | $218,570.04 |
DisclosureSEC source: 0001209191-21-030400 · doc4.xml · nonDerivative · entry 5 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 893,563 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $181.53 to $182.50. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 04, 2021 Filed May 5, 2021 21:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 505 | $180.94 | $91,372.38 |
DisclosureSEC source: 0001209191-21-030400 · doc4.xml · nonDerivative · entry 4 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 894,763 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $180.51 to $181.08. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 04, 2021 Filed May 5, 2021 21:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 200 | $179.71 | $35,941.00 |
DisclosureSEC source: 0001209191-21-030400 · doc4.xml · nonDerivative · entry 3 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 895,268 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $179.42 to $179.99. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 04, 2021 Filed May 5, 2021 21:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 9,792 | $11.48 | $112,412.16 |
DisclosureSEC source: 0001209191-21-030400 · doc4.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 895,468 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| May 04, 2021 Filed May 5, 2021 21:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 5,208 | $5.04 | $26,248.32 |
DisclosureSEC source: 0001209191-21-030400 · doc4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 885,676 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| April 06, 2021 Filed Apr 8, 2021 20:34 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 9,792 | $0.00 Strike: $11.48 | $0.00 |
DisclosureSEC source: 0001209191-21-026074 · doc4.xml · derivative · entry 13 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,088 Underlying: Class A Common Stock · 9,792 shares Expires 2029-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F11 · derivative.exercise_date: This option, originally for 145,786 shares, of which 38,698 have been exercised, vested as to one forty-eighth of the shares on May 1, 2019, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| April 06, 2021 Filed Apr 8, 2021 20:34 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 5,208 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-21-026074 · doc4.xml · derivative · entry 12 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,990 Underlying: Class A Common Stock · 5,208 shares Expires 2028-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F10 · derivative.exercise_date: This option, originally for 250,000 shares, of which 155,010 have been exercised, vested as to one forty-eighth of the shares on October 1, 2018, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| April 06, 2021 Filed Apr 8, 2021 20:34 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 100 | $199.41 | $19,941.00 |
DisclosureSEC source: 0001209191-21-026074 · doc4.xml · nonDerivative · entry 11 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 880,468 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| April 06, 2021 Filed Apr 8, 2021 20:34 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 800 | $198.69 | $158,953.04 |
DisclosureSEC source: 0001209191-21-026074 · doc4.xml · nonDerivative · entry 10 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 880,568 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F9 · price: This transaction was executed in multiple trades at prices ranging from $198.36 to $199.10. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 06, 2021 Filed Apr 8, 2021 20:34 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,849 | $197.47 | $562,605.14 |
DisclosureSEC source: 0001209191-21-026074 · doc4.xml · nonDerivative · entry 9 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 881,368 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · price: This transaction was executed in multiple trades at prices ranging from $197.10 to $198.04. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 06, 2021 Filed Apr 8, 2021 20:34 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 5,428 | $196.61 | $1,067,222.42 |
DisclosureSEC source: 0001209191-21-026074 · doc4.xml · nonDerivative · entry 8 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 884,217 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $196.09 to $197.08. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 06, 2021 Filed Apr 8, 2021 20:34 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,097 | $195.81 | $214,806.97 |
DisclosureSEC source: 0001209191-21-026074 · doc4.xml · nonDerivative · entry 7 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 889,645 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $195.08 to $196.04. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 06, 2021 Filed Apr 8, 2021 20:34 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,826 | $194.44 | $355,052.01 |
DisclosureSEC source: 0001209191-21-026074 · doc4.xml · nonDerivative · entry 6 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 890,742 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $194.00 to $194.87. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 06, 2021 Filed Apr 8, 2021 20:34 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,900 | $193.48 | $367,604.02 |
DisclosureSEC source: 0001209191-21-026074 · doc4.xml · nonDerivative · entry 5 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 892,568 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $193.00 to $193.97. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 06, 2021 Filed Apr 8, 2021 20:34 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 200 | $192.47 | $38,493.00 |
DisclosureSEC source: 0001209191-21-026074 · doc4.xml · nonDerivative · entry 4 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 894,468 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $191.99 to $192.94. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 06, 2021 Filed Apr 8, 2021 20:34 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 800 | $190.58 | $152,465.04 |
DisclosureSEC source: 0001209191-21-026074 · doc4.xml · nonDerivative · entry 3 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 894,668 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $189.99 to $190.88. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 06, 2021 Filed Apr 8, 2021 20:34 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 9,792 | $11.48 | $112,412.16 |
DisclosureSEC source: 0001209191-21-026074 · doc4.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 895,468 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| April 06, 2021 Filed Apr 8, 2021 20:34 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 5,208 | $5.04 | $26,248.32 |
DisclosureSEC source: 0001209191-21-026074 · doc4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 885,676 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| March 19, 2021 Filed May 27, 2021 00:27 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantStock Option (right to buy) · Derivative | 61,428 | $0.00 Strike: $177.76 | $0.00 |
DisclosureSEC source: 0001209191-21-036104 · doc4.xml · derivative · entry 4 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,428 Underlying: Class A Common Stock · 61,428 shares Expires 2031-03-19 F6 · derivative.exercise_date: This option, granted pursuant to the Issuer's 2019 Omnibus Incentive Plan, vests as to one forty-eighth of the shares on May 1, 2021 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| March 19, 2021 Filed May 27, 2021 00:27 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantClass A Common Stock | 24,571 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-036104 · doc4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 905,039 F1 · shares: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock. One-sixteenth of the RSUs shall vest on May 21, 2021 and on each three-month anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. F2 · balance_after: The number of shares beneficially owned following the reported transaction is as of March 19, 2021. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 9,791 | $0.00 Strike: $11.48 | $0.00 |
DisclosureSEC source: 0001209191-21-020877 · doc4.xml · derivative · entry 10 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,880 Underlying: Class A Common Stock · 9,791 shares Expires 2029-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F9 · derivative.exercise_date: This option, originally for 145,786 shares, of which 28,906 have been exercised, vested as to one forty-eighth of the shares on May 1, 2019, and one-forty-eighth of the subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such dat Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 5,209 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-21-020877 · doc4.xml · derivative · entry 9 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,198 Underlying: Class A Common Stock · 5,209 shares Expires 2028-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · derivative.exercise_date: This option, originally for 250,000 shares, of which 149,802 have been exercised, vested as to one forty-eighth of the shares on October 1, 2018, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,174 | $159.35 | $505,768.01 |
DisclosureSEC source: 0001209191-21-020877 · doc4.xml · nonDerivative · entry 8 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 880,468 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $158.97 to $159.86. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,933 | $158.49 | $306,355.37 |
DisclosureSEC source: 0001209191-21-020877 · doc4.xml · nonDerivative · entry 7 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 883,642 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $157.94 to $158.87. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,384 | $157.42 | $375,284.75 |
DisclosureSEC source: 0001209191-21-020877 · doc4.xml · nonDerivative · entry 6 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 885,575 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $156.93 to $157.87. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,105 | $156.35 | $485,463.02 |
DisclosureSEC source: 0001209191-21-020877 · doc4.xml · nonDerivative · entry 5 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 887,959 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $155.92 to $156.86. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,904 | $155.35 | $451,146.85 |
DisclosureSEC source: 0001209191-21-020877 · doc4.xml · nonDerivative · entry 4 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 891,064 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $154.83 to $155.78. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,500 | $154.37 | $231,550.50 |
DisclosureSEC source: 0001209191-21-020877 · doc4.xml · nonDerivative · entry 3 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 893,968 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $153.815 to $154.71. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 9,791 | $11.48 | $112,400.68 |
DisclosureSEC source: 0001209191-21-020877 · doc4.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 895,468 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 5,209 | $5.04 | $26,253.36 |
DisclosureSEC source: 0001209191-21-020877 · doc4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 885,677 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 01:09 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 892 | $0.00 Strike: $11.48 | $0.00 |
DisclosureSEC source: 0001209191-21-007563 · doc4.xml · derivative · entry 10 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,671 Underlying: Class A Common Stock · 892 shares Expires 2029-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F9 · derivative.exercise_date: This option, originally for 145,786 shares, of which 19,115 have been exercised, vested as to one forty-eighth of the shares on May 1, 2019, and one-forty-eighth of the subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such dat Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 01:09 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 9,108 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-21-007563 · doc4.xml · derivative · entry 9 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,407 Underlying: Class A Common Stock · 9,108 shares Expires 2028-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · derivative.exercise_date: This option, originally for 250,000 shares, of which 144,593 have been exercised, vested as to one forty-eighth of the shares on October 1, 2018, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 01:09 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 200 | $178.98 | $35,796.00 |
DisclosureSEC source: 0001209191-21-007563 · doc4.xml · nonDerivative · entry 8 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 880,468 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $178.97 to $178.99. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 01:09 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 600 | $177.99 | $106,792.02 |
DisclosureSEC source: 0001209191-21-007563 · doc4.xml · nonDerivative · entry 7 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 880,668 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $177.69 to $178.30. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 01:09 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,410 | $176.99 | $249,557.03 |
DisclosureSEC source: 0001209191-21-007563 · doc4.xml · nonDerivative · entry 6 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 881,268 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $176.62 to $177.40. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 01:09 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 4,815 | $175.92 | $847,045.65 |
DisclosureSEC source: 0001209191-21-007563 · doc4.xml · nonDerivative · entry 5 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 882,678 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $175.52 to $176.51 . The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 01:09 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,575 | $175.22 | $451,192.02 |
DisclosureSEC source: 0001209191-21-007563 · doc4.xml · nonDerivative · entry 4 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 887,493 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $174.52 to $175.50. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 01:09 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 400 | $174.15 | $69,660.00 |
DisclosureSEC source: 0001209191-21-007563 · doc4.xml · nonDerivative · entry 3 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 890,068 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $173.48 to $174.41. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 01:09 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 892 | $11.48 | $10,240.16 |
DisclosureSEC source: 0001209191-21-007563 · doc4.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 890,468 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.